Selected Publications

Publication
Review that summarizes clinical research addressing the pathology driving role of fractalkine axis in cardiovascular disease and the potential of KAND567
Shu Xian Loh, Yasemin Ekinci, Luke Spray, Visvesh Jeyalan, Thomas Olin, Gavin Richardson, David Austin, Mohammad Alkhalil, Ioakim Spyridopoulos.
Fractalkine Signalling (CX3CL1/CX3CR1 Axis) as an Emerging Target in Coronary Artery Disease
Read Publication
Publication
In a study with 480 heart attack patients, Professor Ioakim Spyridopoulos and his research group have shown the potential for KAND567 to prolong life after an acute heart attack
Spray L, Park C, Cormack S, Mohammed A, Panahi P, Boag S, Bennaceur K, Sopova K, Richardson G, Stangl VM, Rech L, Rainer PP, Ramos GC, Hofmann U, Stellos K, Spyridopoulos I.
The Fractalkine Receptor CX3CR1 Links Lymphocyte Kinetics in CMV-Seropositive Patients and Acute Myocardial Infarction With Adverse Left Ventricular Remodeling.
Read Publication

Publication
Positive research results for KAND567 may pave the way for new treatment for ovarian cancer
Lehto J, Huguet Ninou A, Chioureas D, Jonkers J, Gustafsson NMS.
Targeting CX3CR1 Suppresses the Fanconi Anemia DNA Repair Pathway and Synergizes with Platinum.
Read Publication
Publication
Study in primary samples from cancer with progressive disease show that KAND567 has capacity to kill leukemic cells by blocking specific immune cells in the leukemia microenvironment
Mohammad Hojjat-Farsangi MSc,PhD , Wen Zhong Ms.C, Tom Mulder MD PhD, Ann Svensson Ms.C, Jeanette Lundin MD PhD, Marzia Palma MD PhD, Johan Schultz PhD, Thomas Olin PhD, Bjorn Wahlin MD PhD, Anders Osterborg MD PhD, Parviz Kokhaei PhD, Hakan Mellstedt MD PhD
A CX3CR1 (fractalkine receptor) Small Molecular Antagonist (rugocrixan) Suppressed the Growth Promoting Effect of Monocytes on Chronic Lymphocytic Leukemia Cells
Read Publication